The antibiotic pipeline cannot be rebuilt by market incentives alone — the science base for novel antibiotic discovery has also atrophied as public research funding shifted elsewhere. OPEN-ABIOTICS creates a permanent, self-funding public R&D infrastructure by redirecting a small share of pharmaceutical industry profits into antibiotic discovery.

2B/year) funds a network of 20 Global Antibiotic Research Nodes (GARNs) — public university labs with standardised equipment, shared compound screening libraries (5M+ compounds), and AI-driven target identification engines.

All GARN discoveries are published open-access with mandatory open licensing for any antibiotic compound that reaches preclinical proof-of-concept, ensuring generic manufacturers can produce at scale from Day 1 of approval. A Commercialisation Bridge Fund ($400M) pays for Phase I–II trials of promising GARN candidates, handing off to subscription/prize mechanisms at Phase III.

This addresses the 'underfunded public R&D' root cause — the one part of the pipeline that market incentives structurally cannot fix.